RYTM
NASDAQ · Biotechnology
Rhythm Pharmaceuticals Inc
$110.64
+5.62 (+5.35%)
Financial Highlights (FY 2026)
Revenue
201.34M
Net Income
-208,537,811
Gross Margin
89.7%
Profit Margin
-103.6%
Rev Growth
+100.2%
D/E Ratio
0.40
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.7% | 35.1% | 35.1% | 35.1% |
| Operating Margin | -101.2% | -2.3% | -2.4% | -2.1% |
| Profit Margin | -103.6% | -2.3% | -2.7% | -2.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 201.34M | 975.71M | 873.25M | 945.71M |
| Gross Profit | 180.66M | 342.40M | 306.44M | 331.87M |
| Operating Income | -203,735,181 | -22,341,461 | -20,627,664 | -19,482,655 |
| Net Income | -208,537,811 | -22,144,056 | -23,253,892 | -24,310,165 |
| Gross Margin | 89.7% | 35.1% | 35.1% | 35.1% |
| Operating Margin | -101.2% | -2.3% | -2.4% | -2.1% |
| Profit Margin | -103.6% | -2.3% | -2.7% | -2.6% |
| Rev Growth | +100.2% | -2.7% | +8.2% | +7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.09B | 1.47B | 1.46B | 1.63B |
| Total Equity | 2.72B | 3.68B | 4.04B | 3.52B |
| D/E Ratio | 0.40 | 0.40 | 0.36 | 0.46 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -202,318,359 | -26,213,634 | -24,112,007 | -26,719,532 |
| Free Cash Flow | — | -20,824,615 | -25,629,049 | -24,210,481 |